Cardiovascular diseases, primarily coronary disease, remain the leading cause of mortality in the majority of countries with well-developed economy. Electropulse therapy (defibrillation) is the main method helpful in life-threatening arrhythmias leading to heart arrest. The development of devices generating biphasic pulses is in progress now. Clinical trials confirmed the capacity of a bipolar pulse to arrest cardiac arrhythmia with current of lower strength in comparison with monopolar pulses. Due to low discharge energy, the degree of postresuscitation myocardial dysfunction is essentially decreased. New technology of biphasic pulses developed by Schiller AG Firm (Switzerland), based on the use of Multipulse Biowave device, is a new step in development of urgent care potentialities in severe cardiac arrhythmias in risk groups.